Pharmafile Logo
Pharmafocus logo
Advanced Search

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023
Medical Communications Dermatology, EC, Litfulo, alopecia

Pfizer has announced that the European Commission (EC) has granted marketing authorisation to Litfulo (ritlecitinib) to treat adult and adolescent …

News

BioNTech and CEPI partner for development of mRNA mpox vaccine

September 19, 2023
Research and Development BioNTech, CEPI, Immunology, mpox

BioNTech and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a partnership to advance the development of mRNA-based vaccine …

News

GSK’s Ojjaara approved by FDA for patients with myelofibrosis and anaemia

September 18, 2023
Medical Communications FDA, GSK, Haematology, Ojjaara, anaemia, myelofibrosis

GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate …

News

Astellas plans to invest over €330m in new facility in Ireland

September 18, 2023
Manufacturing and Production Astellas Pharma, Ireland, Pharmacy, facility, manufacturing

Astellas Pharma has announced that it is preparing to submit a planning application to build a new state-of-the-art facility at …

News

GSK and Save the Children extend partnership for unvaccinated children

September 15, 2023
Medical Communications GSK, Immunology, childhood vaccination, vaccines

GSK and Save the Children have announced that they will be renewing their partnership for an additional five years. GSK …

News

BMS shares new research and development  plans at the company’s R&D day

September 15, 2023
Research and Development BMS, Pharmacy, R&D, development, research

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, US, in order to discuss …

News

Sun Pharma and Pharmazz enter license agreement for Tyvalzi in India

September 14, 2023
Sales and Marketing License Agreement, Neurology, Pharmazz, Sun Pharma, Tyvalzi, sovateltide

Sun Pharma has announced that one of its wholly owned subsidiaries has entered into a license agreement with Pharmazz in …

News

Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA

September 14, 2023
Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom

Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application …

News

Nuvectis Pharma initiates phase 1a NXP900 clinical trial

September 13, 2023
Research and Development Cancer, Nuvectis Pharma, Oncology, clinical trial

Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose escalation clinical study of NXP900, …

News

FDA approves LimFlow system for patients with CLTI

September 13, 2023
Medical Communications CLTI, Devices, FDA, LimFlow

LimFlow SA has announced that the US Food and Drug Administration (FDA) has approved its LimFlow System for the treatment …

News

NHS-integrated pharmacy app Charac receives £1.2m funding

September 12, 2023
Research and Development Charac, Pharmacy, app, digital health, pharmacies

Charac, an NHS-integrated pharmacy app, has raised £1.2m in debt and equity financing from the National Pharmacy Association (NPA) and …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

September 12, 2023
Research and Development Neurocrine Biosciences, Neurology, Sosei Heptares, clinical trial

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human clinical trial to assess the …

News

AstraZeneca and Daiichi Sankyo share positive results from DESTINY-Lung02 phase 2 trial

September 11, 2023
Medical Communications AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology, clinical trial

AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase 2 trial, which showed Enhertu’s …

News

Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America

September 11, 2023
Research and Development Pharmacy, SB17, Sandoz, commercialisation, ustekinumab

Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung Bioepis, providing Sandoz the exclusive …

News

CymaBay shares results from phase 3 RESPONSE trial for seladelpar

September 8, 2023
Research and Development CymaBay, PBC, Pharmacy, clinical trial, seladelpar

CymaBay Therapeutics has announced positive topline results from its phase 3 RESPONSE study which assessed the safety and efficacy of …

News
towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

Vaxart shares topline data from phase 2 study of norovirus vaccine candidate

September 8, 2023
Research and Development Infections and infestations, Vaccine, Vaxart, norovirus

Vaxart has announced topline data from its phase 2 challenge study which assessed its oral tablet monovalent norovirus vaccine candidate. …

News

Valneva and Pfizer share positive results from phase 2 trial for Lyme disease vaccine candidate

September 7, 2023
Medical Communications Infections and infestations, Pfizer, Vaccine, Valneva, clinical trial, lyme disease

Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine candidate, VLA15, …

News

BridgeBio Pharma shares positive feedback from FDA and EMA for phase 3 trial of infigratinib

September 7, 2023
Research and Development BridgeBio Pharma, EMA, FDA, Musculo-skeletal disorder, achondroplasia, clinical trial

BridgeBio Pharma has announced positive feedback from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) on …

News
towfiqu-barbhuiya-msqb97guxy0-unsplash

Abbott to acquire Bigfoot Biomedical

September 6, 2023
Business Services Abbott, Bigfoot Biomedical, Diabetes, acquisition, diabetes

Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however this transaction is still subject …

News

Plus Therapeutics initiates part B of phase 1/2a ReSPECT-LM trial for leptomeningeal metastase

September 6, 2023
Research and Development Oncology, Plus Therapeutics, clinical trial, leptomeningeal metastase

Plus Therapeutics has announced that the first patient has begun treatment in part B of the ReSPECT-LM phase 1/2a dose …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026